Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02385526 · ClinicalTrials.gov registry record
Vagus Nerve Stimulation Titration Protocol to Improve Tolerance and Accelerate Adaptation
A clinical trial, sponsored by Cyberonics.
- Completed
- Registry status
- 67
- Enrollment target
NCT02385526 is a clinical trial that has completed, run by Cyberonics. The registered enrollment target is 67 participants.
The verdict
NCT02385526 has completed, sponsored by Cyberonics.
- COMPLETED
- Registry status
- 67 participants
- Enrollment target
Study Summary
Post-market, on-label, double-blind, randomized, prospective, interventional, tolerability and clinical outcomes study to determine the number of patients achieving their final assigned VNS Therapy dose settings in patients with drug-resistant epilepsy who are being treated with adjunctive VNS Therapy using new titration protocols.
Interventions
- DEVICE Vagus Nerve Stimulation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2015-04-28 |
| Est. Completion | 2016-10-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02385526
The ClinicalTrials.gov registry entry for NCT02385526 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cyberonics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vagus Nerve Stimulation Therapy is the first listed.
NCT02385526 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02385526 about?
NCT02385526 is a clinical study titled "Vagus Nerve Stimulation Titration Protocol to Improve Tolerance and Accelerate Adaptation". Post-market, on-label, double-blind, randomized, prospective, interventional, tolerability and clinical outcomes study to determine the number of patients achieving their final assigned VNS Therapy dose settings in patients with drug-resistant epilepsy who are being treated with adjunctive VNS Thera...
What is the current status of trial NCT02385526?
This trial is currently completed. The enrollment target is 67 participants. The study started on 2015-04-28. Estimated completion is 2016-10-10.
What interventions are being tested in trial NCT02385526?
The interventions under investigation include: Vagus Nerve Stimulation Therapy (DEVICE).
Who is sponsoring clinical trial NCT02385526?
This trial is sponsored by Cyberonics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.